期刊
JOURNAL OF PHARMACEUTICAL SCIENCES
卷 111, 期 1, 页码 274-284出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.xphs.2021.10.017
关键词
Bioequivalence; Dissolution; GastroPlus modeling; Physiologically based pharmacokinetic (PBPK) modeling
资金
- Novartis Pharmaceuticals Corporation
A physiologically based biopharmaceutics model was developed to support the formulation development of ribociclib, a CDK4/6 inhibitor. The model accurately predicted the pharmacokinetics and bioequivalence of ribociclib in healthy volunteers and cancer patients, providing valuable insights for formulation optimization and clinical studies.
A physiologically based biopharmaceutics model (PBBM) was developed to support formulation development of ribociclib, an orally bioavailable selective CDK4/6 inhibitor. Ribociclib is a weak base with moderate permeability and complete in vitro dissolution under stomach pH. GastroPlus (TM) was used to simulate the pharmacokinetics (PK) in healthy volunteers after capsule dosing. Simulations showed rapid, complete dissolution in human stomach without intestinal precipitation and with permeation-controlled absorption. Permeability was identified as controlling the systemic exposure. PBBM predicted bioequivalence (BE) between capsule and tablet in healthy volunteers, despite non-similarity between in vitro dissolution kinetics (f2<50). BE was verified in a clinical study. Then virtual bioequivalence (VBE) simulations predicted comparable PK in cancer patients between capsule and tablet of commercial batch, which was also confirmed in a clinical study. Finally, virtual trial simulations using virtual batches with slower dissolution were used to define an in vitro BE safe-space for tablets, where BE is expected. PBBM can identify drugs with permeability-controlled absorption for which formulation optimization can focus more on manufacturability rather than dissolution. PBBM can be used to predict BE study outcomes, define clinically relevant specification and BE safe-space, superseding dissolution similarity f2 criteria. (C) 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据